Sign in

    Gospel Enyindah-Asonye

    Research Analyst at Morgan Stanley

    Gospel Enyindah-Asonye is an Analyst at Morgan Stanley specializing in biopharmaceuticals, often participating in coverage of companies such as Ventyx Biosciences, Schrodinger Inc, and REGENXBIO during earnings calls and sector events. Known for supporting coverage on innovative biotechnology and therapeutic companies, he has contributed to investment research and analysis within the healthcare sector, but public data on specific success rates, TipRanks rankings, or tracked returns is not available. Enyindah-Asonye began his finance career as a Research Associate at Morgan Stanley & Co. LLC, with no evidence of prior employment at other firms. Professional medical credentials are noted in some profiles, but there is no accessible public record confirming FINRA registration or securities licenses.

    Gospel Enyindah-Asonye's questions to REGENXBIO (RGNX) leadership

    Gospel Enyindah-Asonye's questions to REGENXBIO (RGNX) leadership • Q3 2024

    Question

    Gospel Enyindah-Asonye, on behalf of Vikram Purohit at Morgan Stanley, asked for guidance on how best to interpret the upcoming functional data for the RGX-202 Duchenne program.

    Answer

    Dr. Steve Pakola, Chief Medical Officer, explained that the company will assess the totality of the data, including standard timed function tests like the 10-meter walk/run, NSAA scores, and caregiver-reported outcomes. CEO Curran Simpson added that their analysis will be supported by comparisons to external controls and substantial natural history databases.

    Ask Fintool Equity Research AI

    Gospel Enyindah-Asonye's questions to Kymera Therapeutics (KYMR) leadership

    Gospel Enyindah-Asonye's questions to Kymera Therapeutics (KYMR) leadership • Q3 2024

    Question

    On behalf of Vikram Purohit, Gospel Enyindah-Asonye from Morgan Stanley asked about the ideal partnership structure and potential timing for Kymera's oncology assets, KT-253 and KT-333.

    Answer

    CEO Nello Mainolfi stated that an ideal partner would have a strong clinical and commercial franchise in hematology, where the assets have shown promising activity. This would maximize patient value while allowing Kymera to focus its internal resources on its immunology pipeline. He did not comment on specific timing or ongoing discussions.

    Ask Fintool Equity Research AI

    Gospel Enyindah-Asonye's questions to Ventyx Biosciences (VTYX) leadership

    Gospel Enyindah-Asonye's questions to Ventyx Biosciences (VTYX) leadership • Q1 2024

    Question

    Gospel Enyindah-Asonye of Morgan Stanley asked about the efficacy bar for VTX958 in Crohn's disease that would justify continued development, based on the data expected in the second half of the year.

    Answer

    Executive Martin Auster explained that the primary endpoint is the change in CDAI score. He noted that a meaningful response, competitive with approved biologics, would be in the upper double-digits to low hundreds. For the secondary endpoint of endoscopic response, a competitive result would be in the high teens to low 20s delta versus placebo.

    Ask Fintool Equity Research AI